Team Science: The SU2C Dream Team Initiative

Size: px

Start display at page:

Download "Team Science: The SU2C Dream Team Initiative"

Sylvia Gallagher
5 years ago
Views:

1 Team Science: The SU2C Dream Team Initiative Pat J. Morin, Ph.D. Director, Scientific Review and Grants Administration American Association for Cancer Research SU2C Dream Teams at a Glance SU2C Dream Teams Grants ($6 Million -$22 Million; 3-4 years) Translational Multi-institutional (Large collaborating Teams) Near Term impact to patients First grants awarded in

2 Stand up to Cancer (SU2C) SU2C is a program of the Entertainment Industry Foundation created in 2008 to accelerate innovative cancer research that will get new therapies to patients quickly. SU2C is bringing together large teams of exceptional researchers and is encouraging collaboration rather than competition. By galvanizing the entertainment industry, SU2C creates awareness and builds broad public support for this effort. SU2C-Funded Research Grants (Leaders) (Partners) Funding # of Scientists # of Institutions Breast Cancer (Slamon Gray) $17,500, Epigenetics (Baylin/Jones) $10,220, PI3K (Cantley/Mills) $16,100, CTC Chip (Haber/Toner) $15,000, Pancreatic Cancer (Thompson Von Hoff Drebin) $22,000, Melanoma (Trent/LoRusso) (SU2C MRA) $6,000, Prostate (Chinnaiyan/Sawyers )(SU2C PCF) $10,000, Prostate (Small/Witte) (SU2C PCF) $10,000, Immunotherapy (Allison/Ribas) (SU2C CRI) $10,000, Pediatrics (Maris/Mackall) (SU2C St. Baldrick s) $14,500, SU2C KWF Dream Team $8,000,000 TOTALS $139,320,

3 Oregon Health & Science University Oregon Health & Science University Knight Cancer Institute California Institute of Technology (CalTech) Cancer Commons City of Hope Lawrence Berkeley National Laboratory Salk Institute for Biological Studies Sanford Burnham Medical Research Institute Scripps Translational Science Institute (STSI) Stanford University UCLA Jonsson Comprehensive Cancer Center UCSF Helen Diller Family Comprehensive Cancer Center University of California, Berkeley University of California, Davis University of California, Davis Cancer Center University of California, Los Angeles University of California, San Diego University of California, San Francisco University of California, Santa Cruz University of Southern California USC Norris Comprehensive Cancer Center University of British Columbia BC Cancer Agency The Vancouver Prostate Center Fred Hutchinson Cancer Research Center Seattle Children's Research Institute University of Washington Affiliated Institutions Comprehensive Cancer Centers of Nevada Lovelace Respiratory Research Institute Karmanos Cancer Institute (KCI) Michigan State University University of Michigan University of Michigan Comprehensive Cancer Center Wayne State University Mayo Clinic Rochester McMaster University University of Wisconsin Children's Hospital of Philadelphia Magee Women's Hospital Temple University Temple University, Fels Institute for Cancer Research and Molecular Biology University of Pennsylvania University of Pennsylvania Abramson Cancer Center University of Pittsburgh University of Pittsburgh Cancer Institute University of Pittsburgh Medical Center Indiana University Northwestern University The Hospital for Sick Children Boston Children's Hospital Brigham & Women's Hospital Dana Farber Cancer Institute Harvard Medical School Massachusetts General Hospital The Broad Institute Beth Israel Deaconess Medical Center Cold Spring Harbor Laboratory Columbia University Columbia University Herbert Irving Comprehensive Cancer Center Memorial Sloan Kettering Cancer Center Mount Sinai School of Medicine New York University Weill Cornell Medical College Princeton University University of Medicine & Dentistry of New Jersey Howard Hughes Medical Institute Johns Hopkins University Johns Hopkins University Kimmel Comprehensive Cancer Center National Cancer Institute Georgetown University, Lombardi Comprehensive Cancer Center Lineberger Comprehensive Cancer Center, University of North Carolina Map includes ONLY institutions represented by Dream Team Members currently working on SU2C funded research Mayo Clinic Scottsdale Biodesign Institute at Arizona State University Translational Genomics Research Institute (TGen) Baylor College of Medicine Baylor College of Medicine, Duncan Cancer Center Texas Children's Cancer Center Texas Oncology Baylor Charles A. Sammons Cancer Center University of Texas M.D. Anderson Cancer Center Mayo Clinic Florida 5 International Institutions Australia Queensland Institute for Medical Research The George Institute for Global Health Netherlands Erasmus Medical Center Netherlands Cancer Institute University Medical Center Utrecht Spain Centro Nacional de Investigaciones Oncológicas (CNIO) Vall d'hebron Institute of Oncology UK Institute of Cancer Research Royal Mardsen Hospital The Institute of Cancer Research Original 2009 SU2C Dream Teams An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and Their Resistance Phenotypes - Slamon-Gray Bioengineering and Clinical Applications of Circulating Tumor Cell Chip Haber/Toner Bringing Epigenetic Therapy to the Forefront of Cancer Management Baylin/Jones Cutting off the Fuel Supply: A New Approach to the Treatment of Pancreatic Cancer - Thompson-Von Hoff- Drebin Targeting the PI3K Pathway in Women's Cancers Cantley/Mills 3

4 New Dream Teams Targeting Adaptive Pathways in Metastatic Treatment- Resistant Prostate Cancer (SU2C-PCF) Small/Witte Precision Therapy of Advanced Prostate Cancer (SU2C-PCF) Chinnaiyan/Sawyers Personalized Medicine for Patients With BRAF Wild- Type (BRAFwt) Cancer (SU2C-MRA) Trent/LoRusso Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy (SU2C-CRI) Allison-Ribas Immunogenomics to Create New Therapies for High- Risk Childhood Cancers (SU2C-St. Baldrick s) - Maris/Mackall SU2C Scientific Advisory Committee (SAC) Phillip A. Sharp, Ph.D., Chairperson Arnold J. Levine, Ph.D., Vice Chair William G. Nelson, M.D., Ph.D., Vice Chair Julian Adams, Ph.D. Angelika Amon, Ph.D. Kenneth C. Anderson, M.D., Ph.D. Frederick R. Appelbaum, M.D. Elizabeth H. Blackburn, Ph.D. Richard B. Gaynor, M.D. William N. Hait, M.D., Ph.D. Lee J. Helman, M.D. Waun Ki Hong, M.D. Carl H. June, M.D. William G. Kaelin Jr., M.D. Michael B. Kastan, M.D., Ph.D. Richard D. Kolodner, Ph.D. Guillermina (Gigi) Lozano, Ph.D. Thomas J. Lynch Jr., M.D. Tak W. Mak, Ph.D. Cecil B. Pickett, Ph.D. Nancy A. Roach Laura K. Shawver, Ph.D. Ellen V. Sigal, Ph.D. David A. Tuveson, M.D., Ph.D. 4

5 SU2C Dream Team Process Scope of the grant is determined by the SAC Press release announcement issued (Call for Ideas), marketing Receive LOIs (6 weeks) Teams develop ideas and submit full proposals (6 weeks) Teleconference to select top ideas for full proposal submission (3 4) SAC scores and critiques ideas on proposalcentral. In person selection meeting: Teams present their ideas, winning Team selected SU2C approval: EIF Board of Directors approval Awardees notified, press release issued Project starts Subcontracts between lead institution and other institutions Grant Agreement (contract) negotiated with lead institution SAC Review Team Constituted Submission of Progress Reports (every 6 months) Progress review visits (every 6 months) SU2C Model What is the definition of success? Number of publications? Number of patents? Number of clinical trials? Number of new drugs tested? Leverage funds? Scientific impact and patient benefit! 5

6 New York Times, Jan 22, 2013 New York Times, Sept 6,

7 2009 Dream Team Publications Dream Team Collaborations Pediatric CTC Prostate 1 Prostate 2 PI3K SU2C Data Portal Breast Immunology Pancreatic Epigenetic Melanoma 7

8 Mandatory Meetings SU2C Annual Summit SU2C DT leaders present their latest findings and are reviewed by the SAC Highly collaborative environment SU2C activities at the AACR Annual Meeting Dream Teams have in-person meetings Meetings with other Dream Team Leaders and SAC Presentations at open sessions Clinical Trials Summary 49 trials planned 41 trials currently active 13 trials completed 3,075 patients enrolled in SU2C clinical trials to date 8

9 Industry collaboration (28) Industry Partners # Epigenetics PI3K Breast Cancer CTC Chip Pancreatic Melanoma Prostate (1) Prostate (2) Immunology Pediatric Abbott 1 Amgen (incl. Dompe s.p.a.) 3 Aragon Pharmaceuticals 2 Astellas 1 Astex Pharmaceuticals 1 AstraZeneca 5 Bayer Pharmaceuticals 1 Biomarin 1 Bristol Myers Squibb 3 Celgene (incl. Abraxis Bioscience) 2 Eli Lilly & Company (incl. ImClone Systems) 2 Exelixis 2 GSK 5 Janssen 2 MedImmune 1 Medivation 1 Merck 2 Myriad Genetics 1 Novartis 5 OncoGenex Pharmaceuticals 2 OSI Pharmaceuticals 1 Pfizer 2 Plexxikon 1 ProGen 1 Roche (Genentech) 4 Sanofi Aventis 1 Syndax Pharmaceuticals 1 Takeda/Millenium Difficulties of Large Multi-Institutional Teams: Lessons learned Coordination of Research Projects-Collaboration. Because of the size of the Teams, coordinating research to maximize efficiency and scientific output can be challenging. Importance of dynamic leaders Frequent face-to-face meetings and teleconferences (mandatory) Project manager Delay in contract execution. This is often due to inconsistent communication between the Investigators and the Institutions contract administration staff during the contract negotiation phase. Frequent follow up from the AACR Deadline for contract execution Involvement from Leader (PIs) Inconsistencies in contract language. Some Institutions are state agencies that have very specific laws regarding liability insurance, indemnification, reporting period, etc. Have a standard subcontract, and try to insist on consistent language Keep track of differences and adapt process 9

10 Difficulties of Large Multi-Institutional Teams: Lessons learned Intellectual property. Currently, AACR/SU2C does not claim any rights to I.P., but multi-institutional agreements sometimes have different viewpoints on how the I.P. matters should be resolved. Involve PIs Communication. It is the Lead Institution s responsibility to inform AACR on all matters related to press releases, publishing of peer reviewed articles, or any other general press related to the Team, but is not done on a consistent basis. Provide PIs with clear information at the beginning of the grant regarding expectations (toolkit) Project Managers, PIOs Accuracy of Progress/Financial Reports. Challenges related to the Leader reviewing and approving financial reports and progress reports prior to submission to the AACR. Project Manager Constant interactions with Institution Financial/Grant Office Summary SU2C has provided, through the Dream Team concept, a new, innovative model for accelerating cancer research and for translating findings from bench to bedside in a short timeframe. Teams being evaluated based on conventional metrics as well as on cancer patient impact. Large teams have definite set of challenges, but most can be addressed with appropriate measures. 10

TEAM SCIENCE IN THE NEW ERA OF CANCER RESEARCH AND TRANSLATIONAL MEDICINE

TEAM SCIENCE IN THE NEW ERA OF CANCER RESEARCH AND TRANSLATIONAL MEDICINE Margaret Foti, PhD, MD (hc) Chief Executive Officer SWOG Meeting San Francisco, CA April 26-29, 2017 American Association for Cancer